Target Name: CD1A
NCBI ID: G909
Other Name(s): OTTHUMP00000018907 | R4 | T-cell surface antigen T6/Leu-6 | CD1A antigen, a polypeptide | T-cell surface glycoprotein CD1a | T6 | hTa1 thymocyte antigen | cortical thymocyte antigen CD1A | differentiation antigen CD1-alpha-3 | Cluster of differentiation 1 A | epidermal dendritic cell marker CD1a | CD1 | CD1a | CD1a molecule | FCB6 | CD1A variant 1 | cluster of differentiation 1 A | CD1A_HUMAN | HTA1 | Differentiation antigen CD1-alpha-3 | T-cell surface glycoprotein CD1a (isoform 1) | CD1a molecule, transcript variant 1 | Cortical thymocyte antigen CD1A | Epidermal dendritic cell marker CD1a

CD1A as a Potential Drug Target and Biomarker: An Overview

Introduction

CD1A, a component of the major histocompatibility complex (MHC) class I molecules, is a highly conserved transmembrane protein that plays a crucial role in cell-to-self and self-to-cell communication. CD1A is expressed in most tissues and is involved in various cellular processes, including immune response, inflammation, and tissue repair. Its functions make it an attractive target for drug development, as modifying CD1A expression levels can potentially lead to therapeutic benefits for various diseases. In this article, we will discuss CD1A as a drug target and biomarker, highlighting its current status in research and its potential therapeutic implications.

CD1A as a Drug Target

CD1A has been identified as a potential drug target due to its critical role in the immune response. CD1A is involved in the presentation of antigens to the T-cells, which is crucial for triggering an immune response. mice deficient in CD1A showed reduced responses to antigens, suggesting that modulating CD1A levels could improve immune responses.

CD1A has also been shown to play a role in cancer progression. High levels of CD1A have been observed in various types of cancer, including breast, ovarian, and colorectal cancer. Additionally, CD1A has been linked to cancer stem cells (CSCs), which are responsible for the development and maintenance of cancer. Therefore, targeting CD1A could potentially lead to the inhibition of cancer stem cell activity.

CD1A as a Biomarker

CD1A has also been used as a biomarker for various diseases, including cancer, autoimmune disorders, and disease.

CD1A has been used as a marker for cancer, as high levels of CD1A have been observed in various types of cancer. For example, in breast cancer, CD1A levels have been shown to be higher in the malignant tissue compared to the surrounding tissue. This suggests that CD1A could be a potential biomarker for breast cancer and could be used for the development of new diagnostic tools and therapeutic approaches.

CD1A has also been used as a marker for autoimmune disorders, as these disorders often involve an overactive immune response. For example, in rheumatoid arthritis (RA), CD1A levels have been shown to be higher in the synovial tissue compared to the surrounding tissue. This suggests that CD1A could be a potential biomarker for RA and could be used for the development of new diagnostic tools and therapeutic approaches.

CD1A has also been used as a biomarker for psoriasis, as these disorders often involve an overactive immune response. For example, in psoriasis, CD1A levels have been shown to be higher in the skin compared to the surrounding tissue. This suggests that CD1A could be a potential biomarker for psoriasis and could be used for the development of new diagnostic tools and therapeutic approaches.

Conclusion

In conclusion, CD1A is a highly conserved transmembrane protein that plays a crucial role in cell-to-self and self-to-cell communication. Its functions make it an attractive target for drug development, as modifying CD1A expression levels can potentially lead to therapeutic benefits for various diseases. Furthermore, CD1A has also been used as a biomarker for various diseases, including cancer, autoimmune disorders, and ancient diseases. As research continues to advance, the potential of CD1A as a drug target and biomarker will continue to be explored , providing new insights into the biology of CD1A and its potential therapeutic applications.

Protein Name: CD1a Molecule

Functions: Antigen-presenting protein that binds self and non-self lipid and glycolipid antigens and presents them to T-cell receptors on natural killer T-cells

More Common Targets

CD1B | CD1C | CD1D | CD1E | CD2 | CD200 | CD200R1 | CD200R1L | CD207 | CD209 | CD22 | CD226 | CD24 | CD244 | CD247 | CD248 | CD24P2 | CD27 | CD27-AS1 | CD274 | CD276 | CD28 | CD2AP | CD2BP2 | CD3 Complex (T Cell Receptor Complex) | CD300A | CD300C | CD300E | CD300LB | CD300LD | CD300LD-AS1 | CD300LF | CD300LG | CD302 | CD320 | CD33 | CD34 | CD36 | CD37 | CD38 | CD3D | CD3E | CD3G | CD4 | CD40 | CD40LG | CD44 | CD44-DT | CD46 | CD47 | CD48 | CD5 | CD52 | CD53 | CD55 | CD58 | CD59 | CD5L | CD6 | CD63 | CD68 | CD69 | CD7 | CD70 | CD72 | CD74 | CD79A | CD79B | CD8 | CD80 | CD81 | CD81-AS1 | CD82 | CD83 | CD84 | CD86 | CD8A | CD8B | CD8B2 | CD9 | CD93 | CD96 | CD99 | CD99L2 | CD99P1 | CDA | CDADC1 | CDAN1 | CDC123 | CDC14A | CDC14B | CDC14C | CDC16 | CDC20 | CDC20-DT | CDC20B | CDC20P1 | CDC23 | CDC25A | CDC25B